ArticleEMBO molecular medicine2021
Rational design of West Nile virus vaccine through large replacement of 3' UTR with internal poly(A).
Article in EMBO molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Duplication of specialized cis-acting elements SLI and SLIII in the viral RNA 3'UTR enables mosquito-borne orthoflavivirus adaptation to avian hosts.Nucleic acids research · 2026Article
- Construction and Evaluation of a Chimeric Japanese Encephalitis Virus Vaccine Candidate Strain with Chaoyang Virus as the Backbone.Vaccines · 2025Article
- West Nile Virus in a changing climate: epidemiology, pathology, advances in diagnosis and treatment, vaccine designing and control strategies, emerging public health challenges - a comprehensive review.Emerging microbes & infections · 2025Review
- West Nile virus vaccine candidates attenuated by dinucleotide enrichment are immunogenic and protective against lethal infection.PLoS pathogens · 2025Article
- Infectious Subgenomic Amplicon Strategies for Japanese Encephalitis and West Nile Viruses.Journal of medical virology · 2025Article
- A safer cell-based yellow fever live attenuated vaccine protects mice against YFV infection.iScience · 2024Article
- Subgenomic Flaviviral RNAs of Dengue Viruses.Viruses · 2023Review
- Flaviviruses in AntiTumor Therapy.Viruses · 2023Review
- Sequence duplication in 3' UTR modulates virus replication and virulence of Japanese encephalitis virus.Emerging microbes & infections · 2022Article
- In Vitro and In Vivo Characterization of a New Strain of Mosquito Flavivirus Derived fromViruses · 2022Article
- Rational design of West Nile virus vaccine through large replacement of 3' UTR with internal poly(A).EMBO molecular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Flavivirus comprises numerous emerging and re-emerging arboviruses causing human illness. Vaccines are the best approach to prevent flavivirus diseases. But pathogen diversities are always one of the major hindrances for timely development of new vaccines when confronting unpredicted flavivirus outbreaks. We used West Nile virus (WNV) as a model to develop a new live-attenuated vaccine (LAV), WNV-poly(A), by replacing 5' portion (corresponding to SL and DB domains in WNV) of 3'-UTR with internal poly(A) tract. WNV-poly(A) not only propagated efficiently in Vero cells, but also was highly attenuated in mouse model. A single-dose vaccination elicited robust and long-lasting immune responses, conferring full protection against WNV challenge. Such "poly(A)" vaccine strategy may be promising for wide application in the development of flavivirus LAVs because of its general target regions in flaviviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.